SPECIALTY GUIDELINE MANAGEMENT

TALZENNA (talazoparib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Talzenna is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (*gBRCAm*) HER-2 negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for Talzenna.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Breast cancer

Authorization of 12 months may be granted for the treatment of human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in members with deleterious or suspected deleterious germline BRCA mutations as detected by an FDA-approved companion diagnostic test.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

1. Talzenna [package insert]. New York, NY: Pfizer Inc.; October 2018.

Talzenna

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

